Abstract
The concentration of kynurenic acid (KYNA) in the cerebrospinal fluid, which is in the nanomolar range, is known to decrease in epilepsy. The experimental data suggest that treatment with l-KYN dose dependently increases the concentration of the neuroprotective KYNA in the brain, which itself hardly crosses the blood–brain barrier. However, it is suggested that new synthetic KYNA analogs may readily cross the blood–brain barrier. In this study, we tested the hypothesis that a new KYNA analog administered systemically in a sufficient dose results in a decreased population spike activity recorded from the pyramidal layer of area CA1 of the hippocampus, and also provides protection against pentylenetetrazole-induced epileptiform seizures.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beadle GW, Mitchell HK et al (1947) Kynurenine as an intermediate in the formation of nicotinic acid from tryptophane by neurospora. Proc Natl Acad Sci USA 33(6):155–158
Foster AC, Vezzani A et al (1984) Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett 48(3):273–278
Fulop F, Szatmari I et al (2009) Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem 16(36):4828–4842
Gellert L, Fuzik J et al (2011) Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur J Pharmacol 667(1–3):182–187
Hicks RR, Smith DH et al (1994) Kynurenate is neuroprotective following experimental brain injury in the rat. Brain Res 655(1–2):91–96
Kaminski RM, Zielinska E et al (2003) Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy. Pol J Pharmacol 55(5):741–746
Klivenyi P, Toldi J et al (2004) Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv Exp Med Biol 541:169–183
Kocki T, Wielosz M et al (2006) Enhancement of brain kynurenic acid production by anticonvulsants–novel mechanism of antiepileptic activity? Eur J Pharmacol 541(3):147–151
Nemeth H, Robotka H et al (2004) Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology 47(6):916–925
Okuno E, Nakamura M et al (1991a) Two kynurenine aminotransferases in human brain. Brain Res 542(2):307–312
Okuno E, Schmidt W et al (1991b) Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations. J Neurochem 57(2):533–540
Rozsa E, Robotka H et al (2008) The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of l-kynurenine to kynurenic acid: an in vitro study. Brain Res Bull 76(5):474–479
Scharfman HE, Ofer A (1997) Pretreatment with l-kynurenine, the precursor to the excitatory amino acid antagonist kynurenic acid, suppresses epileptiform activity in combined entorhinal/hippocampal slices. Neurosci Lett 224(2):115–118
Schwarcz R, Pellicciari R (2002) Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303(1):1–10
Stone TW (1988) Comparison of kynurenic acid and 2-APV suppression of epileptiform activity in rat hippocampal slices. Neurosci Lett 84(2):234–238
Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45(3):309–379
Stone TW (2000) Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 21(4):149–154
Stone TW (2001) Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol 64(2):185–218
Swartz KJ, During MJ et al (1990) Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 10(9):2965–2973
Vamos E, Pardutz A et al (2009) The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci 283(1–2):21–27
Vecsei L, Miller J et al (1992) Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 28(2):233–238
Yamamoto H, Murakami H et al (1995) Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children. Brain Dev 17(5):327–329
Zadori D, Klivenyi P et al (2009) Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm 116(11):1403–1409
Acknowledgments
The present study was supported by TÁMOP—4.2.1/B-09/1/KONV-2010-0005; -4.2.2/B-10/1-2010-0012; OTKA K75628 and Neurosciene Research Group of the Hungarian Academy of Sciences and University of Szeged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Demeter, I., Nagy, K., Gellért, L. et al. A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study. J Neural Transm 119, 151–154 (2012). https://doi.org/10.1007/s00702-011-0755-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-011-0755-x